Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Epidemic H1N1 Infection and Declining Immunity Among people
4.2.2 Technological Advancements in the Vaccines Field
4.3 Market Restraints
4.3.1 High costs of H1N1 Vaacines
4.3.2 Lengthy Manufacturing Process of H1N1 Vaacines
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Inactivated Vaccine
5.1.2 Live Attenuated Vaccine
5.2 By Route of Administration
5.2.1 Intradermal Vaccines
5.2.2 Intramuscular Vaccines
5.2.3 Intranasal Vaccines
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 MedImmune LLC (AstraZeneca PLC)
6.1.2 Sanofi Pasteur AG
6.1.3 GlaxoSmithKline Plc
6.1.4 Abbott Laboratories
6.1.5 CSL Limited (Seqirus GmbH)
6.1.6 Pfizer Inc
6.1.7 CPL Biologicals Pvt. Ltd
6.1.8 Mitsubishi Tanabe Pharma Corporation
6.1.9 Sinovac Biotech Ltd
6.1.10 Zydus Cadila


7 MARKET OPPORTUNITIES AND FUTURE TRENDS